Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Nova Eye Medical's enterprise value is $25.01 Mil.
Nova Eye Medical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-4.57 Mil. Therefore, Nova Eye Medical's EV-to-EBITDA for today is -5.48.
The historical rank and industry rank for Nova Eye Medical's EV-to-EBITDA or its related term are showing as below:
ELXMF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -39.19 Med: -3.63 Max: 99.43
Current: -5.14
During the past 13 years, the highest EV-to-EBITDA of Nova Eye Medical was 99.43. The lowest was -39.19. And the median was -3.63.
ELXMF's EV-to-EBITDA is ranked worse than 100% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 13.845
vs ELXMF: -5.14
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Nova Eye Medical (OTCPK:ELXMF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Nova Eye Medical's PE Ratio (TTM) for today is calculated as:
Nova Eye Medical's share price for today is $0.01431.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nova Eye Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.017.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Nova Eye Medical's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Nova Eye Medical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nova Eye Medical EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nova Eye Medical's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nova Eye Medical's EV-to-EBITDA falls into.
Nova Eye Medical's current Enterprise Value is $25.01 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nova Eye Medical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-4.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nova Eye Medical (ELXMF) has a EV-to-EBITDA of -5.48 as of Jul. 25, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Nova Eye Medical. According to the industry distribution chart, Nova Eye Medical ranks #999999 out of 510 companies in the Medical Devices & Instruments industry.
Is Nova Eye Medical's EV-to-EBITDA too high?
Nova Eye Medical's current EV-to-EBITDA is -5.48. Based on the distribution chart, Nova Eye Medical ranks #999999 out of 510 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Nova Eye Medical has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Nova Eye Medical's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nova Eye Medical ranks #999999 out of 510 companies for EV-to-EBITDA. This places Nova Eye Medical in the lower half of its industry. The industry median EV-to-EBITDA is 13.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 13.85, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Nova Eye Medical. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 13.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nova Eye Medical's current EV-to-EBITDA is -5.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nova Eye Medical stock overvalued right now?
Nova Eye Medical (ELXMF) has a current EV-to-EBITDA of -5.48. The stock's GF Value™ is $0.02, compared to a current price of $0.01 — trading 28.5% below its estimated fair value. The current EV-to-EBITDA is -5.48. Nova Eye Medical's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Nova Eye Medical (ELXMF), the current EV-to-EBITDA is -5.48 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nova Eye Medical (ELXMF) Overvalued in 2026?
Based on GuruFocus' analysis, Nova Eye Medical stock appears to be undervalued.
The current stock price of $0.01 is trading 28.5% below its estimated GF Value™ of $0.02.
Key valuation signals for ELXMF:
EV-to-EBITDA: -5.48
GF Value™: $0.02 vs. price of $0.01 (28.5% below fair value)
No single metric tells the full story. See the ELXMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nova Eye Medical Ltd develops and sells surgical devices for the treatment of glaucoma, a cause of blindness. In addition, the company is involved in the commercialisation of the subthreshold nano-pulse ophthalmic laser, 2RT, for the treatment of retinal disease via the AlphaRET segment. The company's reportable segments are: Glaucoma Surgical Devices and AlphaRET. The majority of its revenue is generated from the Glaucoma Surgical Devices segment, which is involved in the design, manufacture, marketing, and sale of the iTrack, iTrack Advance, and the Molteno3 glaucoma surgical device. These are all single-use surgical devices. Geographically, the company generates maximum revenue from the United States of America, followed by Europe, the Asia Pacific, Other regions, and Australia.
48GF Score
Get the complete analysis for ELXMF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELXMF has been successfully added to your 
